Suven Life Sciences is currently trading at Rs. 28.50, up by 0.80 points or 2.89% from its previous closing of Rs. 27.70 on the BSE.
The scrip opened at Rs. 27.55 and has touched a high and low of Rs. 30.40 and Rs. 27.05 respectively. So far 3,17,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 35.25 on 13-Dec-2012 and a 52 week low of Rs. 13.75 on 27-Jun-2012.
Last one week high and low of the scrip stood at Rs. 29.00 and Rs. 24.80 respectively. The current market cap of the company is Rs. 332 crore.
The promoters holding in the company stood at 63.44% while Institutions and Non-Institutions held 0.02% and 36.54% respectively.
Suven Life Sciences (Suven) has secured four product patents, two from China, one from Mexico and one from New Zealand corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2028.
With these new patents, Suven has a total of ten granted patents from China, fourteen from Mexico & fourteen from New Zealand. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
Suven Life Sciences is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets.
